Express Pharma

Cipla posts full year revenue worth Rs 15,219 cr

4

PAT is at Rs 1,411 crore in FY 2018

The company reported full year revenues of Rs 15,219 crores, growing 6 per cent y-o-y. For the quarter ended March 31, the company reported revenues of Rs 3,698 crores, growing 5 per cent y-o-y. EBITDA margins, before exceptional items, increased by over 160 bps to 18.6 per cent. The company’s profit after tax in FY 18 is at Rs 1,411 crore and in Q4 FY18 it is Rs 179 crore.

The R&D investments in the quarter ramped up to ~7.6 per cent of revenues. Key markets including India and South Africa continued to deliver strong growth.

Umang Vohra, Managing Director and Global Chief Executive Officer, Cipla, said, “This financial year, our focus remained on strengthening our portfolio and deepening our presence in priority markets. We are happy that our efforts on cost and efficiency improvement helped us deliver the full year margin ahead of our guidance range. Our focus for next year will be to continue our growth trajectory in key markets and investments in portfolio for sustainable growth. We continue to strive to make a difference to patients through meeting unmet needs and our continuing focus on quality and innovation.”

Comments are closed.